Morgan Stanley has reaffirmed its “overweight” rating on Reliance Industries Limited (RIL), setting a target price of ₹1,662. This indicates a potential upside of 37% from the current market price of ₹1,211.50.
The brokerage highlighted RIL’s strategic plans to leverage its technological expertise and extensive distribution networks to build a more integrated healthcare system. This includes initiatives such as digital health platforms, telemedicine services, and advanced healthcare delivery models, which are expected to position the company as a key player in the healthcare sector.
Morgan Stanley remains confident in RIL’s ability to innovate and diversify across sectors, reinforcing its optimistic outlook for the stock.
Disclaimer:
This article is for informational purposes only and does not constitute financial advice. Please consult a qualified financial advisor before making investment decisions.
